Brigatinib for Non-Small Cell Lung Cancer
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Recruiting
Observational Study
Non-small Cell Lung Cancer (NSCLC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Takeda · Industry
Who this trial is looking for
This trial is looking for Japanese people with advanced non-small cell lung cancer. Participants will take Brigatinib tablets for one year while doctors monitor for side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with unresectable advanced non-small cell lung cancer
- I have an ALK fusion gene-positive diagnosis
You may not be able to join if
- I have a history of allergic reactions to Brigatinib
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.
Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
Contacts